Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 23479363)

1.

Composite three-marker assay for early detection of kidney cancer.

Su Kim D, Choi YD, Moon M, Kang S, Lim JB, Kim KM, Park KM, Cho NH.

Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):390-8. doi: 10.1158/1055-9965.EPI-12-1156.

2.

Panel of candidate biomarkers for renal cell carcinoma.

Kim DS, Choi YP, Kang S, Gao MQ, Kim B, Park HR, Choi YD, Lim JB, Na HJ, Kim HK, Nam YP, Moon MH, Yun HR, Lee DH, Park WM, Cho NH.

J Proteome Res. 2010 Jul 2;9(7):3710-9. doi: 10.1021/pr100236r.

PMID:
20455597
3.

Serum levels of nicotinamide N-methyltransferase in patients with lung cancer.

Tomida M, Mikami I, Takeuchi S, Nishimura H, Akiyama H.

J Cancer Res Clin Oncol. 2009 Sep;135(9):1223-9. doi: 10.1007/s00432-009-0563-y. Epub 2009 Feb 26.

PMID:
19242722
4.

Nicotinamide N-methyltransferase protein expression in renal cell cancer.

Zhang J, Xie XY, Yang SW, Wang J, He C.

J Zhejiang Univ Sci B. 2010 Feb;11(2):136-43. doi: 10.1631/jzus.B0900249.

5.

Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.

Jou YC, Tsai YS, Hsieh HY, Chen SY, Tsai HT, Chen KJ, Wang ST, Shiau AL, Wu CL, Tzai TS.

Urol Oncol. 2013 Nov;31(8):1806-11. doi: 10.1016/j.urolonc.2012.03.011. Epub 2012 May 19.

PMID:
22609059
6.

Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.

Roessler M, Rollinger W, Palme S, Hagmann ML, Berndt P, Engel AM, Schneidinger B, Pfeffer M, Andres H, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W, Tacke M.

Clin Cancer Res. 2005 Sep 15;11(18):6550-7.

7.

Tumor M2 pyruvate kinase in plasma of patients with urological tumors.

Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA.

Tumour Biol. 2001 Sep-Oct;22(5):282-5.

PMID:
11553857
8.

Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.

Xu G, Xiang CQ, Lu Y, Kang XN, Liao P, Ding Q, Zhang YF.

Cancer Lett. 2009 Sep 18;282(2):205-13. doi: 10.1016/j.canlet.2009.03.017. Epub 2009 Apr 11.

PMID:
19362769
9.

Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.

Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M, Vyzula R, Slaby O.

J Transl Med. 2012 Mar 22;10:55. doi: 10.1186/1479-5876-10-55.

10.

Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma.

Yao M, Tabuchi H, Nagashima Y, Baba M, Nakaigawa N, Ishiguro H, Hamada K, Inayama Y, Kishida T, Hattori K, Yamada-Okabe H, Kubota Y.

J Pathol. 2005 Feb;205(3):377-87.

PMID:
15682440
11.

Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.

Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, Kikuno N, Tanaka Y, Majid S, Nakagawa M, Igawa M, Dahiya R.

Clin Cancer Res. 2006 Dec 1;12(23):6989-97.

12.

Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).

Wechsel HW, Petri E, Bichler KH, Feil G.

Anticancer Res. 1999 Jul-Aug;19(4A):2583-90.

PMID:
10470199
13.

Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma.

Win KT, Lee SW, Huang HY, Lin LC, Lin CY, Hsing CH, Chen LT, Li CF.

Tumour Biol. 2013 Dec;34(6):3923-31. doi: 10.1007/s13277-013-0980-z. Epub 2013 Jul 11.

PMID:
23838801
14.

Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.

Kroeze SG, Bijenhof AM, Bosch JL, Jans JJ.

Cancer Biomark. 2010;7(6):261-8. doi: 10.3233/CBM-2010-0195. Review.

PMID:
21694464
15.

Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.

Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA, Jung K.

Cancer Lett. 2008 Sep 28;269(1):85-92. doi: 10.1016/j.canlet.2008.04.022. Epub 2008 May 27.

PMID:
18504068
16.

Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test.

Sartini D, Muzzonigro G, Milanese G, Pozzi V, Vici A, Morganti S, Rossi V, Mazzucchelli R, Montironi R, Emanuelli M.

Cell Biochem Biophys. 2013 Apr;65(3):473-83. doi: 10.1007/s12013-012-9451-1.

PMID:
23097023
17.

Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma.

Sartini D, Muzzonigro G, Milanese G, Pierella F, Rossi V, Emanuelli M.

J Urol. 2006 Nov;176(5):2248-54.

PMID:
17070307
18.

Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker.

Ljungberg B, Rasmuson T, Grankvist K.

Eur Urol. 1992;21(2):160-3.

PMID:
1499617
19.
20.

The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.

Weinberger R, Appel B, Stein A, Metz Y, Neheman A, Barak M.

Eur J Cancer Care (Engl). 2007 Jul;16(4):333-7.

PMID:
17587357
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk